Elanco Animal Health Inc (ELAN)

$12.9

+0.08

(+0.62%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $12.78
    $13.14
    $12.90
    downward going graph

    0.97%

    Downside

    Day's Volatility :2.78%

    Upside

    1.83%

    downward going graph
  • $8.52
    $18.80
    $12.90
    downward going graph

    33.95%

    Downside

    52 Weeks Volatility :54.68%

    Upside

    31.38%

    downward going graph

Returns

PeriodElanco Animal Health IncSector (Health Care)Index (Russel 2000)
3 Months
-3.32%
6.5%
0.0%
6 Months
-15.55%
7.1%
0.0%
1 Year
5.25%
9.8%
0.0%
3 Years
-64.2%
14.2%
-20.2%

Highlights

Market Capitalization
6.4B
Book Value
$12.26
Earnings Per Share (EPS)
-2.65
PEG Ratio
1.84
Wall Street Target Price
19.43
Profit Margin
-29.83%
Operating Margin TTM
11.04%
Return On Assets TTM
1.03%
Return On Equity TTM
-19.24%
Revenue TTM
4.4B
Revenue Per Share TTM
8.86
Quarterly Revenue Growth YOY
-4.1000000000000005%
Gross Profit TTM
2.5B
EBITDA
878.0M
Diluted Eps TTM
-2.65
Quarterly Earnings Growth YOY
-0.71
EPS Estimate Current Year
0.94
EPS Estimate Next Year
1.05
EPS Estimate Current Quarter
0.26
EPS Estimate Next Quarter
0.24

Analyst Recommendation

Buy
    66%Buy
    28%Hold
    4%Sell
Based on 21 Wall street analysts offering stock ratings for Elanco Animal Health Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
6
6
6
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 50.62%

Current $12.90
Target $19.43

Company Financials

FY18Y/Y Change
Revenue
3.1B
↑ 6.15%
Net Income
86.5M
↓ 127.84%
Net Profit Margin
2.82%
↑ 13.57%
FY19Y/Y Change
Revenue
3.1B
↑ 0.14%
Net Income
67.9M
↓ 21.5%
Net Profit Margin
2.21%
↓ 0.61%
FY20Y/Y Change
Revenue
3.3B
↑ 6.59%
Net Income
-560.1M
↓ 924.89%
Net Profit Margin
-17.11%
↓ 19.32%
FY21Y/Y Change
Revenue
4.8B
↑ 45.57%
Net Income
-472.0M
↓ 15.73%
Net Profit Margin
-9.91%
↑ 7.2%
FY22Y/Y Change
Revenue
4.4B
↓ 7.28%
Net Income
-74.0M
↓ 84.32%
Net Profit Margin
-1.67%
↑ 8.24%
FY23Y/Y Change
Revenue
4.4B
↓ 0.02%
Net Income
-1.2B
↑ 1563.51%
Net Profit Margin
-27.87%
↓ 26.2%
Q4 FY22Q/Q Change
Revenue
988.0M
↓ 3.89%
Net Income
-54.0M
↑ 10.2%
Net Profit Margin
-5.47%
↓ 0.7%
Q1 FY23Q/Q Change
Revenue
1.3B
↑ 27.23%
Net Income
103.0M
↓ 290.74%
Net Profit Margin
8.19%
↑ 13.66%
Q2 FY23Q/Q Change
Revenue
1.1B
↓ 15.91%
Net Income
-97.0M
↓ 194.17%
Net Profit Margin
-9.18%
↓ 17.37%
Q3 FY23Q/Q Change
Revenue
1.1B
↑ 1.04%
Net Income
-1.1B
↑ 1029.9%
Net Profit Margin
-102.62%
↓ 93.44%
Q4 FY23Q/Q Change
Revenue
1.0B
↓ 3.09%
Net Income
-141.0M
↓ 87.14%
Net Profit Margin
-13.62%
↑ 89.0%
Q1 FY24Q/Q Change
Revenue
1.2B
↑ 16.43%
Net Income
32.0M
↓ 122.7%
Net Profit Margin
2.66%
↑ 16.28%
FY18Y/Y Change
Total Assets
9.0B
↑ 0.18%
Total Liabilities
3.8B
↑ 227.03%
FY19Y/Y Change
Total Assets
9.0B
↑ 0.32%
Total Liabilities
3.4B
↓ 8.52%
FY20Y/Y Change
Total Assets
17.7B
↑ 96.9%
Total Liabilities
9.2B
↑ 168.02%
FY21Y/Y Change
Total Assets
16.5B
↓ 6.84%
Total Liabilities
8.9B
↓ 2.95%
FY22Y/Y Change
Total Assets
15.5B
↓ 6.02%
Total Liabilities
8.2B
↓ 8.31%
FY23Y/Y Change
Total Assets
14.4B
↓ 7.29%
Total Liabilities
8.1B
↓ 0.77%
Q4 FY22Q/Q Change
Total Assets
15.5B
↑ 3.63%
Total Liabilities
8.2B
↓ 0.01%
Q1 FY23Q/Q Change
Total Assets
15.8B
↑ 1.79%
Total Liabilities
8.3B
↑ 1.06%
Q2 FY23Q/Q Change
Total Assets
15.8B
↑ 0.17%
Total Liabilities
8.4B
↑ 1.05%
Q3 FY23Q/Q Change
Total Assets
14.3B
↓ 9.19%
Total Liabilities
8.2B
↓ 1.98%
Q4 FY23Q/Q Change
Total Assets
14.4B
↑ 0.13%
Total Liabilities
8.1B
↓ 0.86%
Q1 FY24Q/Q Change
Total Assets
14.0B
↓ 2.39%
Total Liabilities
8.0B
↓ 2.16%
FY18Y/Y Change
Operating Cash Flow
487.3M
↑ 180.38%
Investing Cash Flow
-127.0M
↓ 86.83%
Financing Cash Flow
-35.2M
↓ 104.15%
FY19Y/Y Change
Operating Cash Flow
224.1M
↓ 54.01%
Investing Cash Flow
-234.8M
↑ 84.88%
Financing Cash Flow
-304.8M
↑ 765.91%
FY20Y/Y Change
Operating Cash Flow
-41.0M
↓ 118.3%
Investing Cash Flow
-4.8B
↑ 1935.43%
Financing Cash Flow
5.0B
↓ 1725.3%
FY21Y/Y Change
Operating Cash Flow
483.0M
↓ 1278.05%
Investing Cash Flow
-530.0M
↓ 88.91%
Financing Cash Flow
210.0M
↓ 95.76%
FY22Y/Y Change
Operating Cash Flow
452.0M
↓ 6.42%
Investing Cash Flow
-179.0M
↓ 66.23%
Financing Cash Flow
-549.0M
↓ 361.43%
Q4 FY22Q/Q Change
Operating Cash Flow
13.0M
↓ 93.12%
Investing Cash Flow
-76.0M
↑ 105.41%
Financing Cash Flow
-84.0M
↓ 50.3%
Q1 FY23Q/Q Change
Operating Cash Flow
-145.0M
↓ 1215.38%
Investing Cash Flow
-55.0M
↓ 27.63%
Financing Cash Flow
174.0M
↓ 307.14%
Q2 FY23Q/Q Change
Operating Cash Flow
61.0M
↓ 142.07%
Investing Cash Flow
-43.0M
↓ 21.82%
Financing Cash Flow
39.0M
↓ 77.59%
Q3 FY23Q/Q Change
Operating Cash Flow
198.0M
↑ 224.59%
Investing Cash Flow
-36.0M
↓ 16.28%
Financing Cash Flow
-157.0M
↓ 502.56%

Technicals Summary

Sell

Neutral

Buy

Elanco Animal Health Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Elanco Animal Health Inc
Elanco Animal Health Inc
-28.66%
-15.55%
5.25%
-64.2%
-61.34%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Elanco Animal Health Inc
Elanco Animal Health Inc
NA
NA
1.84
0.94
-0.19
0.01
NA
12.26
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Elanco Animal Health Inc
Elanco Animal Health Inc
Buy
$6.4B
-61.34%
NA
-29.83%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Elanco Animal Health Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.03B → 1.20B (in $), with an average increase of 14.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -1.09B → 32.0M (in $), with an average increase of 609.0% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 40.2%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 116.8%

Institutional Holdings

  • Dodge & Cox

    16.97%

  • PRIMECAP Management Company

    10.70%

  • Vanguard Group Inc

    9.97%

  • BlackRock Inc

    5.39%

  • T. Rowe Price Associates, Inc.

    4.48%

  • Black Creek Investment Management Inc

    4.08%

Corporate Announcements

  • Elanco Animal Health Inc Earnings

    Elanco Animal Health Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

elanco is a global animal health company. our vision: food and companionship enriching life. elanco fulfills this vision through three primary pursuits: - helping deliver a safe, more affordable, more abundant food supply by improving the health and performance of animals - helping pets live longer, healthier, higher-quality lives - improving food safety elanco employees are empowered to preserve elanco’s common culture of humility, discipline and involvement. we have a responsibility to connect and contribute to our cause, to be passionate about delivering solutions and value to our customers, and to embrace opportunities for personal and professional growth and development. through innovative products, quality systems and a shared vision, elanco strives daily to enhance animal health—and enrich the lives of people worldwide.

Organization
Elanco Animal Health Inc
Employees
9300
CEO
Mr. Jeffrey N. Simmons
Industry
Process Industries

Discover More

FAQs